Ferocious - Plant Growth Optimizer
Subsidiaries in R & D
Biomendus, Medical Subsidiary
Tygrus' Senior Medical Advisor, Dr. Anthony Atala, has begun developing acute lung inhalation studies on the COVID-19
virus. Initial tests will be conducted on a synthetic lung, heart, liver, and colon designed at The Wake Forest Institute of
Regenerative Medicine. The organs will be infected with the virus and then treated with Tydracin at low concentrations levels.
Upon completion of successful testing the Company will look to schedule both animal and human trials.
Personal Care Subsidiary See Appendix 3
Tygrus' research partner developed a water treatment system using our acid that may eliminate the need for preservatives
in personal care products to achieve the required shelf life. This chemistry, Tydreau, has proven to be effective at values
ranging from 3.5pH to 10.5pH based on numerous tests conducted over the last 4 years. Third-party laboratories have
validated these studies and the Company is in the process of testing with leading industry co-packers.
Tydrolyte, Battery Subsidiary See Appendix 4
Tydrolyte is anticipated to be a potential replacement for the commodity sulfuric acid electrolyte used in lead batteries. Lead
batteries are a $40+ billion/year market, and the sulfuric acid cost of materials represents ~1% of the retail battery value or a
$400M/year market. Lead batteries are used in several major applications including automotive starter lighting and ignition
(SLI), traction drive (forklifts, golf carts, Chinese e-bikes), backup power (telecom, data center), and grid storage.View entire presentation